Valemetostat DS-3201|cas:1809336-39-7|西域试剂

Valemetostat DS-3201,99.65%

产品编号：Bellancom-109108| CAS NO：1809336-39-7| 分子式：C₂₆H₃₄ClN₃O₄| 分子量：488.02

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-109108		￥2500.00	杭州北京（现货）
Bellancom-109108		￥4200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Valemetostat DS-3201

产品介绍

Valemetostat (DS-3201) 是一种首创的 EZH1/2 抑制剂，IC₅₀ 值＜10 nM。Valemetostat 可用于复发以及难治型周围 T 细胞淋巴瘤的研究。

生物活性

Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma.

体外研究

Valemetostat (1-1000 nM) strongly and specifically inhibits EZH1 and EZH2 with IC₅₀ values ＜10 nM.
Valemetostat (100 nM; 7 d) effectively removes H3K27me3 and also prevents unexpected gain of H3K27me3.
Valemetostat (0.1-100 nM; 7 d) potently inhibits H3K27me3 by low-dose treatment in the sensitive lymphoma types.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Valemetostat (0.01 mg/g; i.p.; once) prevents the changes of H3K27me3 after exercise training.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice with chronic and acute running exercise or without exercise
Dosage:	0.01 mg/g
Administration:	Intraperitoneal injection; 0.01 mg/g; 30 min before the start of running exercise
Result:	Significantly increased the level of H3K27me3 , slightly decresed EZH1 level , upregulated the EZH2 level and increased the level of phosphorylated AMPK after exercise. Repressed myonuclear H3K27me3 accumulation during training and caused a failure of adaptive changes.

体内研究

Valemetostat (0.01 mg/g; i.p.; once) prevents the changes of H3K27me3 after exercise training.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6J mice with chronic and acute running exercise or without exercise
Dosage:	0.01 mg/g
Administration:	Intraperitoneal injection; 0.01 mg/g; 30 min before the start of running exercise
Result:	Significantly increased the level of H3K27me3 , slightly decresed EZH1 level , upregulated the EZH2 level and increased the level of phosphorylated AMPK after exercise. Repressed myonuclear H3K27me3 accumulation during training and caused a failure of adaptive changes.

性状

Solid

溶解性数据

In Vitro:

DMSO : 70 mg/mL (143.44 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0491 mL	10.2455 mL	20.4910 mL
5 mM	0.4098 mL	2.0491 mL	4.0982 mL
10 mM	0.2049 mL	1.0245 mL	2.0491 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 5 mg/mL (10.25 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (10.25 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 5 mg/mL (10.25 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (10.25 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 3.5 mg/mL (7.17 mM); Clear solution

此方案可获得 ≥ 3.5 mg/mL (7.17 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 35.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。